Atara Biotherapeutics, Inc. (ATRA)
USD 9.81
(-5.22%)
USD 9.81
(-5.22%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 8.57 Million | 63.57 Million | 20.34 Million | - | - | - |
| Cost of Revenue | 8.88 Million | 14.56 Million | 11.38 Million | 9.86 Million | 8.1 Million | 3.78 Million |
| Gross Profit | -313 Thousand | 49 Million | 8.96 Million | -9.86 Million | -8.1 Million | -3.78 Million |
| Operating Expenses | 275.69 Million | 344.08 Million | 360.8 Million | 309.05 Million | 295.68 Million | 237.11 Million |
| Selling, General and Administrative Expenses | 49.79 Million | 71.55 Million | 78.8 Million | 64.4 Million | 79.58 Million | 69.65 Million |
| Research and Development Expenses | 224.78 Million | 272.53 Million | 282 Million | 244.65 Million | 216.09 Million | 167.45 Million |
| Other Expenses | - | -700 Thousand | - | - | - | - |
| Cost and Expenses | 284.57 Million | 344.08 Million | 360.8 Million | 309.05 Million | 295.68 Million | 237.11 Million |
| Operating Income | -276 Million | -280.51 Million | -340.46 Million | -309.05 Million | -295.68 Million | -237.11 Million |
| Interest Expense | 5.28 Million | 1.98 Million | - | - | - | - |
| Income Tax Expense | 15 Thousand | 12 Thousand | 46 Thousand | 15 Thousand | 12 Thousand | -44 Thousand |
| Earnings before Tax | -276.11 Million | -228.29 Million | -340.09 Million | -306.6 Million | -290.96 Million | -230.74 Million |
| Net Income | -276.12 Million | -2.28 Billion | -3.4 Billion | -3.06 Billion | -2.9 Billion | -2.3 Billion |
| Earnings Per Share Basic | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 |
| Earnings Per Share Diluted | -65.18 | -55.96 | -90.78 | -103.63 | -141.78 | -131.64 |
| Weighted Average Shares Outstanding | 4.23 Million | 4.07 Million | 3.74 Million | 2.95 Million | 2.05 Million | 1.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 4.23 Million | 4.07 Million | 3.74 Million | 2.95 Million | 2.05 Million | 1.75 Million |
| Gross Margin | -0.04 | 0.77 | 0.44 | - | - | - |
| EBIT Margin | -31.03 | -5.20 | -16.74 | - | - | - |
| Profit Margin | -32.21 | -35.91 | -167.23 | - | - | - |
| EBITDA | -265.99 Million | -213.72 Million | -331.11 Million | -296.73 Million | -282.85 Million | -233.33 Million |
| Earnings Before Tax Margin | -32.19 | -4.41 | -16.74 | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 28.64 Million | 27.35 Million | 8.57 Million | 4.25 Million | 2.13 Million | 957 Thousand |
| Cost of Revenue | 4.62 Million | 1.98 Million | 8.88 Million | 3.16 Million | 2.61 Million | 2.89 Million |
| Gross Profit | 24.01 Million | 25.37 Million | -313 Thousand | 1.09 Million | -477 Thousand | -1.93 Million |
| Operating Expenses | 41.88 Million | 51.86 Million | 268.96 Million | 54.36 Million | 69.13 Million | 69.47 Million |
| Selling, General and Administrative Expenses | 8.91 Million | 9.75 Million | - | 10.38 Million | 12.24 Million | 13.33 Million |
| Research and Development Expenses | 32.97 Million | 42.11 Million | - | 43.98 Million | 56.88 Million | 56.14 Million |
| Other Expenses | -6000.00 | 68 Thousand | -246 Thousand | -12 Thousand | -27 Thousand | -10 Thousand |
| Cost and Expenses | 46.51 Million | 53.85 Million | 277.84 Million | 57.52 Million | 71.75 Million | 72.37 Million |
| Operating Income | -17.87 Million | -26.49 Million | -269.27 Million | -53.27 Million | -69.61 Million | -71.41 Million |
| Interest Expense | 1.26 Million | 1.15 Million | 5.28 Million | 1.17 Million | 1.39 Million | 1.37 Million |
| Income Tax Expense | 171.44 Million | 24 Thousand | 15 Thousand | 11 Thousand | -19 Thousand | 1000.00 |
| Earnings before Tax | -19.04 Million | -31.72 Million | -276.11 Million | -60.43 Million | -69.81 Million | -71.1 Million |
| Net Income | -190.49 Million | -317.52 Million | -2.76 Billion | -604.5 Million | -697.97 Million | -711.08 Million |
| Earnings Per Share Basic | -3.10 | -5.75 | - | -14.09 | -16.26 | -17.00 |
| Earnings Per Share Diluted | -3.10 | -5.65 | - | -14.09 | -16.26 | -16.92 |
| Weighted Average Shares Outstanding | 61.43 Million | 55.22 Million | 42.36 Million | 42.91 Million | 42.91 Million | 41.82 Million |
| Weighted Average Shares Outstanding (Diluted) | 61.43 Million | 56.23 Million | 42.36 Million | 42.91 Million | 42.91 Million | 42.03 Million |
| Gross Margin | 0.84 | 0.93 | -0.04 | 0.26 | -0.22 | -2.03 |
| EBIT Margin | -0.58 | -0.92 | - | -12.25 | -31.44 | -71.61 |
| Profit Margin | -6.65 | -11.61 | -322.09 | -142.17 | -326.46 | -743.03 |
| EBITDA | -16.54 Million | -25.1 Million | - | -52.07 Million | -67.21 Million | -68.52 Million |
| Earnings Before Tax Margin | -0.62 | -0.97 | -31.41 | -12.53 | -32.56 | -74.62 |
MBUMF
STG
001420
TCM1
VCT
CRMZ